Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Drug

Laekna Advances Obesity Treatment Candidate LAE102 with Subcutaneous Dosing in Phase I Study

Fineline Cube Oct 18, 2024

Laekna, a Sino-US biotech firm, has announced the commencement of a subcutaneous dosing cohort within...

Company Deals

Sanofi Invests EUR 300 Million in Joint Venture with Orano Med for Next-Generation Radioligand Therapies

Fineline Cube Oct 18, 2024

Sanofi (EPA: SAN), a leading French pharmaceutical company, has entered into a strategic agreement with...

Company Drug

Antengene’s Xpovio Secures Expanded Access in South Korea for Multiple Myeloma Treatment

Fineline Cube Oct 18, 2024

Antengene Corp., Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that it has received...

Company Drug

AbbVie’s Vyalev Wins FDA Approval as First Subcutaneous Levodopa Therapy for Advanced Parkinson’s

Fineline Cube Oct 18, 2024

AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the US, has received approval from...

Policy / Regulatory

Chengdu Drafts Comprehensive Policy to Stimulate Biomedical Industry Growth

Fineline Cube Oct 18, 2024

The Chengdu Municipal Bureau of Economic and Information Technology has unveiled a draft proposal titled...

Company Drug

Chongqing Zhifei Biological’s EC Injection Receives Market Approval in Indonesia

Fineline Cube Oct 18, 2024

Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a leading biopharmaceutical company based in China, has...

Company Deals

Tencent Invests USD 30 Million in Early Cancer Detection Firm Insighta, Backed by Prenetics

Fineline Cube Oct 18, 2024

Prenetics Global Limited (NASDAQ: PRE), a prominent health sciences company with operations in the US...

Company Deals

LaNova Medicines Secures RMB 300 Million in Series C1 Financing to Advance Cancer Therapy Pipeline

Fineline Cube Oct 18, 2024

LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the successful completion of...

Company

Abbott Laboratories Posts 9.4% Q3 Sales Growth, Driven by Medical Devices and Pharmaceuticals

Fineline Cube Oct 18, 2024

Abbott Laboratories (NYSE: ABT), a U.S.-based healthcare giant, has reported its financial results for the...

Company Deals

Chengdu Baiyu Pharmaceutical Strikes Licensing Deal with Novartis for Unannounced Anti-Tumor Asset

Fineline Cube Oct 18, 2024

Chengdu Baiyu Pharmaceutical Co., Ltd., a Chinese pharmaceutical company, has entered into a licensing agreement...

Company Deals

Cryofocus Medtech Partners with Guangzhou Medical University Hospital for Cryoballoon Ablation R&D

Fineline Cube Oct 17, 2024

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based leader in cryoablation treatment, and the...

Company Drug

Kintor Pharmaceutical Initiates Phase II/III Trial for KX-826 Tincture 1.0% in Treating Male Androgenetic Alopecia

Fineline Cube Oct 17, 2024

Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the commencement...

Company Medical Device

Novocure’s Optune Lua Wins FDA Approval for mNSCLC Treatment in Combination with Immunotherapies

Fineline Cube Oct 17, 2024

Novocure (NASDAQ: NVCR), a Swiss firm renowned for its pioneering Tumor Treating Fields (TTFields) cancer...

Company Deals

Servier and HUST Forge Partnership to Cultivate Innovative Therapies through SHINEDocs Program

Fineline Cube Oct 17, 2024

French pharmaceutical company Servier has joined forces with Huazhong University of Science and Technology (HUST),...

Company Drug

Innovent Biologics’ Picankibart Achieves Positive Results in Phase II UC Study

Fineline Cube Oct 17, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company

Bayer AG Launches China Innovation Hub to Boost Local R&D and Global Integration

Fineline Cube Oct 17, 2024

Bayer AG (ETR: BAYN), a German multinational pharmaceutical and life sciences giant, has announced the...

Company Deals

Lexicon Pharmaceuticals Strikes Licensing Deal with Viatris for Global Expansion of Sotagliflozin

Fineline Cube Oct 17, 2024

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has entered into a licensing agreement with Viatris Inc. (NASDAQ:...

Company Drug

Johnson & Johnson’s Nipocalimab Shows Promise in Treating Adolescent Myasthenia Gravis in Phase II/III Trial

Fineline Cube Oct 17, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a US pharmaceutical giant, has reported encouraging outcomes from...

Policy / Regulatory

NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud

Fineline Cube Oct 17, 2024

The National Healthcare Security Administration (NHSA) has issued a notification aimed at standardizing the management...

Policy / Regulatory

Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024

Fineline Cube Oct 17, 2024

On October 16, 2024, Shanxi Province’s drug procurement platform announced a notice regarding the submission...

Posts pagination

1 … 277 278 279 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.